l||||l|||||||||||||||||||||||||||||||l||||||||l||||||||||||||||||||||||||l| USO0H002260H

(19) United States (12) Statutory Invention Registration (10) Reg. N0.2 Toleikis (54)

(43) Published:

STENTS COMBINED WITH PACLITAXEL

2005/0181977 A1

DERIVATIVES

(75)

Inventor:

Philip M. Toleikis, Vancouver (CA)

8/2005 Hunter et al. ................ .. 514/2

W0

WO 91/12779

9/ 199 1

OTHER PUBLICATIONS Fleischer, David E., et al., “A NeW Coated SelfiExpanding Metal Stent for Malignant Esophageal Strictures, ” Gas Zroinleslinal Endoscopy 38(4):4944196, 1992. Stierle, Andrea, et al., “Taxol and Taxane Production by Taxomyces andreanae, an Endophytic Fungus of Paci?c

(21) APPI'NO'Z 11/357’368 (22) Filed; Feb_ 17, 2006 Related US. Application Data Provisional application No. 60/653,844, ?led on Feb. 17,

2005' (51) Int_ CL A611?‘ 2/00

Jul. 5, 2011

FOREIGN PATENT DOCUMENTS

(73) Assignee: Angiotech International AG, Zug (CH)

(60)

US H2260 H

YeW, ” Science 260Z214*216, Apr. 9, 1993.

Wani, M.C., et al., “Plant Antitumor Agents. V1. The Isola tion and Structure of Taxol, a Novel Antileukemic and Anti tumor Agent from Taxus brevifolia, ” Journal of the Ameri

(200601)

can Chemical Society, 93(9):2325*2327, May 5, 1971. (52)

US. Cl.

..................................................... ..

(58)

Field Of Classi?cation Search ................. .. 424/423

Pnmary ExammeriMlchene Clement

See application ?le for complete search history.

(57)

(56)

424/423

References Cited

.

.

.

ABSTRACT

Stents are used in combination With a paclitaxel derivative in order to inhibit scarring that may otherwise occur When the

us PATENT DOCUMENTS

implant is placed Within an animal. Suitable implants

4,876,399 A

10/1989 Holton et a1‘ _____________ __ 568/817

include vascular stents, esophageal stents, tracheal or bron

4,942,184 A 5,352,806 A

7/1990 HaugWitZ et al. ......... .. 514/449 10/1994 Gunawardana et a1. 549/510

0111211 Stents, gastrointestinal Stents, genital-urinary Stents, nasal and sinus stents, and ENT stems.

5,440,056 A 5,468,769

A

5,616,608 A 5,716,981 A 5,733,925

A

6,074,659 A 6,171,609 B1 6,268,390 B1

8/1995 11/1995

Klein et a1. ............... .. 549/510 Klein et a1.

.....

. . . ..

4/1997 Kinsella et a1. . 2/1998 Hunter et a1. 3/1998

KunZ et a1.

6/2000 1/2001 7/2001

KllIlZ et a1~ - - - - KunZ ......... .. KunZ ......... ..

.....

514/449

514/449 514/449 . . . ..

_

_

26 Clam“, 19 Drawlng sheets

514/449

- - - ~~ 424/423

A statutory invention registration is not a patent. It has

424/422

the defensive attributes of a patent but does not have the enforceable attributes of a patent. No article or adver tisement or the like may use the term patent, or any term

6,306,421 6,403,635 B1

10/2001 6/2002 Kinsella KunZ et al. et a1. .

5 14/449

6,491,938 B2

12/2002 KunZ et al.

424/423

suggestive of a patent, When referring to a statutory

_____

_ _ _ __ 514/411

invention registration. For more speci?c information on

___________

_ _ _ __ 514/449

6,515,009 B1 6,515,016

B2

6,599,928 B2

2/2003

KunZ et a1,

2/2003

Hunter

7/2003 KunZ et al. ............... .. 514/411

the rights associated With a statutory invention registra

tion see 35 U.S.C. 157.

US. Patent

Jul. 5, 2011

US H2260 H

Sheet 1 0119

cEEmo51=mn5 ~.ME

uEiwHoS2t3Ea:

US. Patent

Jul. 5, 2011

US H2260 H

Sheet 2 0f 19

325Em.03:5. N

.ME

2U6i3o.:62t0a5

US. Patent

Jul. 5, 2011

US H2260 H

Sheet 3 0f 19

80982.m=0%5x.?8:0

cnm2“BEo3>umax:-t=E3u

m.ME

$965S59.w2.63

US. Patent

Jul. 5, 2011

Sheet 5 0f 19

US H2260 H

2T2xh+ 20;:xh.+ 2W2xh+

.MEE.

US. Patent

Jul. 5, 2011

Sheet 6 0f 19

US H2260 H

PCMocn?elfxmon,

4CFig.

US. Patent

Jul. 5, 2011

Sheet 7 0f 19

US H2260 H

/

‘I’ Q a U

'

5W

COLLA GEN/15E

SIROMEL YSIN

GAPDH

Fig. 4D

US. Patent

Jul. 5, 2011

Sheet 8 0f 19

US H2260 H

Ly 290181

GAPDH

11-1 (ng/ml.)

0

‘2o.

20'

Drug (M)

o

o

140*? 10"‘10'5 10-‘

Fig. 5A

v20 _ '20

20

US. Patent

Jul. 5, 2011

Sheet 9 0f 19

US H2260 H

2-Methyl-2,4-Pentanediol (Hexylene Glycol)

Collnganase

GAPQH

IL-‘r (ng/mL)

u

20

20

Drug (u)

o

u

10*? 10''‘ W5 10-‘

Fig. 5B

2o

20

20

US. Patent

Jul. 5, 2011

US H2260 H

Sheet 10 0f 19

Deuierium Oxide 99.9oiomXD

Collagenase

2o

20

0

10-7 ‘0-6 10-5 10-‘

Fig. 5C

20

20

2o

US. Patent

Jul. 5, 2011

US H2260 H

Sheet 11 0119

Glycine Ethyl Ester

.

I

Q

"0'.

Collagenase

.

'Q 3

.

’.

‘r

.I

u

I

O

.

.

'

33, GAL)’. '1 J

I

1....‘

a.’ '0

v.0!

I

v I

GAPDH

lL-I (ng/mL)

Drug (M)

0 0

20

20

o

10''? 1o"6 10“5 10-4

Fig. 51) _

20

20

20

US. Patent

Jul. 5, 2011

US H2260 H

Sheet 13 0f 19

Tubercidin

c.M.mg9m8

\L—-! (ng/mL)

o

20

20

Drug (M)

0

0

10'‘7 10"5 10's 10"‘

Fig. 5F

20

20

20

US. Patent

Jul. 5, 2011

Sheet 14 0f 19

Aluminum Fluoride

wI.In0.anm

Fig. 5G

US H2260 H

US. Patent

Jul. 5, 2011

Sheet 15 0f 19

Epoihilone B

Callagenasa

Fig. 5H

US H2260 H

U.S. Patent

Jul. 5, 2011

Sheet 16 0119

US H2260 H

~

~

_

u 13

w G]l|

18

m [Fm wLOW U

%

3dFR:

_ _ .O _

iczea?m

m..ME

US. Patent

Jul. 5, 2011

i

2

:2.

Sheet 17 0119

3l:08?i .52T?SE6Ex:08m9z:25o3;m05

US H2260 H

R.ME

US. Patent

Jul. 5, 2011

88F. _

_

_ .

+ a

lg“.

Sheet 18 0f 19

?m25.89xw:3uz:502SmQa.5

US H2260 H

%.ME

US. Patent

Jul. 5, 2011

Sheet 19 0119

US H2260 H

a.mi e2. uomqmul %